{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:28:42Z","timestamp":1784032122845,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background. \u2003Streptococcus pneumoniae is a common cause of otitis media (OM) in children; mastoiditis remains an important complication of OM. Limited data are available on the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal otitis.<\/jats:p>\n               <jats:p>Methods. \u2003Investigators from 8 children's hospitals in the United States prospectively collected pneumococcal isolates from middle ear or mastoid cultures from children from 2011 to 2013. Serotype and antibiotic susceptibilities were determined and PCV13 doses for children documented.<\/jats:p>\n               <jats:p>Results. \u2003Over the 3-year period, the proportion of isolates included in PCV13 (plus a related serotype) decreased significantly (P = .0006) among the middle ear\/mastoid isolates (2011, 50% [74\/149]; 2012, 40.5% [47\/116]; 2013, 29% [34\/118]). The number of serotype 19A isolates in 2013 (n = 12, 10.2% of total) decreased 76% compared with the number of 19A isolates in 2011 (n = 50, 33.6% of total). Of the children from whom serotype 19A was isolated (n = 93), 55% had previously received &amp;lt;3 doses of PCV13. The most common non-PCV13 serotypes for the combined years were 35B (n = 37), 21 (n = 20), 23B (n = 20), 15B (n = 18), 11 (n = 17), 23A (n = 14), 15A (n = 14), and 15C (n = 14). The proportion of isolates with a penicillin minimal inhibitory concentration &amp;gt;2 \u00b5g\/mL decreased significantly over the 3 years (2011, 22% [35\/154]; 2012, 20% [24\/118]; 2013, 10% [12\/120]; P &amp;lt; .02).<\/jats:p>\n               <jats:p>Conclusions. \u2003The number of pneumococcal isolates and the percentage of isolates with high-level penicillin resistance from cultures taken from children with OM or mastoiditis for clinical indications have decreased following PCV13 use, largely related to decreases in serotype 19A isolates.<\/jats:p>","DOI":"10.1093\/cid\/civ067","type":"journal-article","created":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T04:57:36Z","timestamp":1423025856000},"page":"1339-1345","source":"Crossref","is-referenced-by-count":50,"title":["Multicenter Surveillance of <i>Streptococcus pneumoniae<\/i> Isolates From Middle Ear and Mastoid Cultures in the 13-Valent Pneumococcal Conjugate Vaccine Era"],"prefix":"10.1093","volume":"60","author":[{"given":"Sheldon L.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Pediatric Infectious Diseases Sections, Baylor College of Medicine 1 , Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly J.","family":"Center","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research 2 , Collegeville, Pennsylvania"},{"name":"Pfizer Vaccine Research 3 , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Barson","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine and Public Health 4 , Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philana","family":"Ling-Lin","sequence":"additional","affiliation":[{"name":"5 Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Romero","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences 6 , Little Rock"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Rady Children's Hospital San Diego 7 , California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Q.","family":"Tan","sequence":"additional","affiliation":[{"name":"Northwestern University 8 Feinberg School of Medicine , , Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"University of Southern California School of Medicine 9 , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Peters","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine 10 , Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gurtman","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research 2 , Collegeville, Pennsylvania"},{"name":"Pfizer Vaccine Research 3 , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Scott","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research 2 , Collegeville, Pennsylvania"},{"name":"Pfizer Vaccine Research 3 , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trammel","sequence":"additional","affiliation":[{"name":"inVentive Health Clinical, Princeton 11 , New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research 2 , Collegeville, Pennsylvania"},{"name":"Pfizer Vaccine Research 3 , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina G.","family":"Hulten","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases Sections, Baylor College of Medicine 1 , Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward O.","family":"Mason","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases Sections, Baylor College of Medicine 1 , Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"2024111411395733800_CIV067C1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"key":"2024111411395733800_CIV067C2","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/S0140-6736(03)13772-5","article-title":"Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study","volume":"361","author":"Veenhoven","year":"2003","journal-title":"Lancet"},{"key":"2024111411395733800_CIV067C3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1542\/peds.2007-0619","article-title":"Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997\u20132004","volume":"121","author":"Zhou","year":"2008","journal-title":"Pediatrics"},{"key":"2024111411395733800_CIV067C4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/INF.0b013e3181c1bc48","article-title":"New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine","volume":"29","author":"Casey","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C5","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1001\/jama.298.15.1772","article-title":"Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children","volume":"298","author":"Pichichero","year":"2007","journal-title":"JAMA"},{"key":"2024111411395733800_CIV067C6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/INF.0b013e31828d9acc","article-title":"Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York","volume":"32","author":"Casey","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/cid\/cis799","article-title":"Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial","volume":"55","author":"Jokinen","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024111411395733800_CIV067C8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1542\/peds.2007-2703","article-title":"Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates","volume":"122","author":"Ongkasuwan","year":"2008","journal-title":"Pediatrics"},{"key":"2024111411395733800_CIV067C9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/INF.0000000000000138","article-title":"Incidence of acute mastoiditis in Colorado children in the pneumococcal conjugate vaccine era","volume":"33","author":"Halgrimson","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/INF.0b013e31821038d9","article-title":"The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea","volume":"30","author":"Stamboulidis","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/INF.0b013e3182357c8d","article-title":"Pathogens implicated in acute otitis media failures after 7-valent pneumococcal conjugate vaccine implementation in France: distribution, serotypes, and resistance levels","volume":"31","author":"Couloigner","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C12","doi-asserted-by":"crossref","first-page":"e54333","DOI":"10.1371\/journal.pone.0054333","article-title":"Dynamics of Streptococcus pneumoniae serotypes causing acute otitis media isolated from children with spontaneous middle-ear drainage over a 12-year period (1999\u20132010) in a region of northern Spain","volume":"8","author":"Alonso","year":"2013","journal-title":"PLoS One"},{"key":"2024111411395733800_CIV067C13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/INF.0b013e318247ef84","article-title":"Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media","volume":"31","author":"Cohen","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C14","article-title":"Efficacy of PCV13 in Prevention of AOM and NP Colonization in Children: First Year of Data From the US","author":"Pichichero","year":"2012"},{"key":"2024111411395733800_CIV067C15","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/ciu683","article-title":"Near elimination of otitis media caused by the PCV13 serotypes in Southern Israel shortly after sequential introduction of PCV7\/PCV13","volume":"59","author":"Ben-Shimol","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024111411395733800_CIV067C16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijporl.2013.12.028","article-title":"Impact of 13-valent pneumococcal conjugate vaccine on otitis media bacteriology","volume":"78","author":"Zhao","year":"2014","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2024111411395733800_CIV067C17","article-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"CLSI","year":"2014"},{"key":"2024111411395733800_CIV067C18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0b013e318275614b","article-title":"Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine","volume":"32","author":"Kaplan","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C19","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/JCM.02199-06","article-title":"Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae","volume":"45","author":"Park","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2024111411395733800_CIV067C20","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1016\/j.vaccine.2011.09.112","article-title":"Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine","volume":"29","author":"Miller","year":"2011","journal-title":"Vaccine"},{"key":"2024111411395733800_CIV067C21","article-title":"Update on Effectiveness and Impact of PCV13 Use among U.S. Children","author":"Moore","year":"2014"},{"key":"2024111411395733800_CIV067C22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/infdis\/jiu213","article-title":"Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England","volume":"210","author":"Moore","year":"2014","journal-title":"J Infect Dis"},{"key":"2024111411395733800_CIV067C23","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1016\/j.vaccine.2014.03.065","article-title":"Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children &lt;5 years: An active prospective nationwide surveillance","volume":"32","author":"Ben-Shimol","year":"2014","journal-title":"Vaccine"},{"key":"2024111411395733800_CIV067C24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/INF.0000000000000279","article-title":"Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts\u2019 children","volume":"33","author":"Loughlin","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/infdis\/jit642","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae\u2014Alaska, 2008\u20132012","volume":"209","author":"Gounder","year":"2014","journal-title":"J Infect Dis"},{"key":"2024111411395733800_CIV067C26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.vaccine.2013.12.003","article-title":"Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era","volume":"32","author":"Zuccotti","year":"2014","journal-title":"Vaccine"},{"key":"2024111411395733800_CIV067C27","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024111411395733800_CIV067C28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2013.3924","article-title":"Trends in otitis media-related health care use in the United States, 2001\u20132011","volume":"168","author":"Marom","year":"2014","journal-title":"JAMA Pediatr"},{"key":"2024111411395733800_CIV067C29","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1016\/j.vaccine.2009.03.017","article-title":"Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics","volume":"27","author":"Poolman","year":"2009","journal-title":"Vaccine"},{"key":"2024111411395733800_CIV067C30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/INF.0b013e3182a6adb7","article-title":"Microbiology of acute mastoiditis and complicated or refractory acute otitis media among hospitalized children in the postvaccination era","volume":"33","author":"Giannakopoulos","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411395733800_CIV067C31","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/lary.21727","article-title":"Pediatric acute mastoiditis in the post-pneumococcal conjugate vaccine era","volume":"121","author":"Choi","year":"2011","journal-title":"Laryngoscope"},{"key":"2024111411395733800_CIV067C32","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1542\/peds.2012-3488","article-title":"The diagnosis and management of acute otitis media","volume":"131","author":"Lieberthal","year":"2013","journal-title":"Pediatrics"},{"key":"2024111411395733800_CIV067C33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/INF.0b013e3182868cc8","article-title":"Commentary: antibiotic recommendations for acute otitis media and acute bacterial sinusitis in 2013\u2014the conundrum","volume":"32","author":"Wald","year":"2013","journal-title":"Pediatr Infect Dis J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/9\/1339\/1132738\/civ067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/9\/1339\/1132738\/civ067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:47:41Z","timestamp":1731584861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/60\/9\/1339\/405630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,2,3]]},"published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ067","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,5,1]]},"published":{"date-parts":[[2015,2,3]]}}}